LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Verve Therapeutics Inc

Uždarymo kaina

11.3 0.53

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

11.24

Max

11.31

Pagrindiniai rodikliai

By Trading Economics

Pajamos

19M

-31M

Pardavimai

20M

33M

Pelnas, tenkantis vienai akcijai

-0.35

Pelno marža

-94.108

Darbuotojai

274

EBITDA

19M

-35M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+34.34% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

604M

992M

Ankstesnė atidarymo kaina

10.77

Ankstesnė uždarymo kaina

11.3

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Verve Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-06-17 11:56; UTC

Įsigijimai, susijungimai, perėmimai

Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion

2025-06-17 14:02; UTC

Įsigijimai, susijungimai, perėmimai

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring. What to Know. -- Barrons.com

2025-06-17 12:12; UTC

Įsigijimai, susijungimai, perėmimai

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring 77%. What to Know. -- Barrons.com

2025-06-17 11:01; UTC

Įsigijimai, susijungimai, perėmimai

This Stock Just Jumped 77% After Eli Lilly Made an Agreed $1.3 Billion Bid -- Barrons.com

2025-06-17 10:47; UTC

Įsigijimai, susijungimai, perėmimai

Eli Lilly: Total Potential Consideration of Up to $13.50 Per Shr in Cash Without Interest >LLY

2025-06-17 10:47; UTC

Įsigijimai, susijungimai, perėmimai

Eli Lilly: Considering Also Includes One Non-Tradeable Contingent Value Right Per Shr That Entitles Holder to Receive Up to an Additional $3 Per Shr >LLY

2025-06-17 10:46; UTC

Įsigijimai, susijungimai, perėmimai

Eli Lilly Will Commence Tender Offer to Acquire All Outstanding Shrs of Verve for Purchase Price of $10.50 Per Shr in Cash >LLY

2025-06-17 10:45; UTC

Įsigijimai, susijungimai, perėmimai

Lilly To Acquire Verve Therapeutics To Advance One-time Treatments For People With High Cardiovascular Risk >LLY VERV

2025-06-17 09:33; UTC

Įsigijimai, susijungimai, perėmimai

Eli Lilly Close to $1.3 Billion Bid for Biotech, Says Report. Verve Therapeutics Stock Soars 80%. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Verve Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

34.34% į viršų

12 mėnesių prognozė

Vidutinis 15.06 USD  34.34%

Aukščiausias 24 USD

Žemiausias 11 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Verve Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

10 ratings

4

Pirkti

6

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

4.1501 / 5.16Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Very Strong Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Verve Therapeutics Inc

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.